Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yuta Miyashi

Showing results (1-10 of 27) with videos related to

Pageof 3
Sort By:
Cureus|October 20, 2025
Curettage and Artificial Bone Graft Using Chevron Osteotomy for Bone Tumor of the Talus: A Report of Three CasesYoshiro Yoshikawa, Hiromichi Oshiro, Yuta Miyashi, et al.
Anticancer Research|December 31, 2024
Relationship Between <sup>18</sup>F-FDG-PET/CT-derived Tumor Glucose Metabolic Activity, Nutritional Risk, and Survival in Patients With Soft-tissue SarcomaHiromichi Oshiro, Kohei Mizuta, Yuta Miyashi, et al.
In Vivo (Athens, Greece)|October 30, 2025
Heterogeneity of Tumor Glucose Metabolism in Schwannomas Between Trunk and Extremities: An Imaging StudyYuta Miyashi, Hiromichi Oshiro, Yoshiro Yoshikawa, et al.
Anticancer Research|April 28, 2026
Sulfasalazine an Inhibitor of System x<sub>C</sub> <sup>-</sup> (Cystine/glutamate Antiporter), Combined With Recombinant Methioninase, Inhibits Both Cancer and Normal Cells, Suggesting Lack of Cancer Selectivity of Cysteine RestrictionJinsoo Kim, Qinghong Han, Shukuan Li, et al.
Frontiers in Oncology|June 19, 2026
Direct comparison of efficacy of combining ivermectin versus five first-line chemotherapy drugs with recombinant methioninase against colon-cancer cellsJinsoo Kim, Qinghong Han, Shukuan Li, et al.
Anticancer Research|January 30, 2026
Lack of Cancer Specificity of Methionine Adenosyltransferase 2A (MAT2A) Inhibitor AG-270 in Combination With Recombinant Methioninase <i>In Vitro</i>Jinsoo Kim, Qinghong Han, Shukuan Li, et al.
Cancer Diagnosis & Prognosis|May 4, 2026
The Combination of Methionine Adenosyltransferase 2A (MAT2A) Inhibitor AG-270 and Recombinant Methioninase Is Not Cancer-selective in a Co-culture Model of Colon Cancer Cells and Normal FibroblastsJinsoo Kim, Qinghong Han, Shukuan Li, et al.
Anticancer Research|November 29, 2025
The Combination of Recombinant Methioninase and Low-dose Chloroquine Selectively Eradicates Colon-Cancer Cells Without Apparent Toxicity on Co-cultured Normal FibroblastsJinsoo Kim, Qinghong Han, Shukuan Li, et al.
Anticancer Research|December 30, 2025
Effect of Recombinant Methioninase Dose and Timing on the Selective and Precise Elimination of Cancer Cells from Co-Cultured Normal Cells and on Methionine-dependent Rescue of Cancer CellsJinsoo Kim, Qinghong Han, Shukuan Li, et al.
Anticancer Research|October 28, 2025
Simultaneous Targeting of Multiple Hallmarks of Cancer With Recombinant Methioninase, Rapamycin and Chloroquine Is Specific and Synergistic to MiaPaCa-2 Pancreatic-Cancer Cells in Contrast to Hs-27 Normal FibroblastsJinsoo Kim, Qinghong Han, Shukuan Li, et al.
Pageof 3

Showing results (1-10 of 27) with videos related to

Sort By:
Pageof 3
Cureus|October 20, 2025
Curettage and Artificial Bone Graft Using Chevron Osteotomy for Bone Tumor of the Talus: A Report of Three CasesYoshiro Yoshikawa, Hiromichi Oshiro, Yuta Miyashi, et al.
Anticancer Research|December 31, 2024
Relationship Between <sup>18</sup>F-FDG-PET/CT-derived Tumor Glucose Metabolic Activity, Nutritional Risk, and Survival in Patients With Soft-tissue SarcomaHiromichi Oshiro, Kohei Mizuta, Yuta Miyashi, et al.
In Vivo (Athens, Greece)|October 30, 2025
Heterogeneity of Tumor Glucose Metabolism in Schwannomas Between Trunk and Extremities: An Imaging StudyYuta Miyashi, Hiromichi Oshiro, Yoshiro Yoshikawa, et al.
Anticancer Research|April 28, 2026
Sulfasalazine an Inhibitor of System x<sub>C</sub> <sup>-</sup> (Cystine/glutamate Antiporter), Combined With Recombinant Methioninase, Inhibits Both Cancer and Normal Cells, Suggesting Lack of Cancer Selectivity of Cysteine RestrictionJinsoo Kim, Qinghong Han, Shukuan Li, et al.
Frontiers in Oncology|June 19, 2026
Direct comparison of efficacy of combining ivermectin versus five first-line chemotherapy drugs with recombinant methioninase against colon-cancer cellsJinsoo Kim, Qinghong Han, Shukuan Li, et al.
Anticancer Research|January 30, 2026
Lack of Cancer Specificity of Methionine Adenosyltransferase 2A (MAT2A) Inhibitor AG-270 in Combination With Recombinant Methioninase <i>In Vitro</i>Jinsoo Kim, Qinghong Han, Shukuan Li, et al.
Cancer Diagnosis & Prognosis|May 4, 2026
The Combination of Methionine Adenosyltransferase 2A (MAT2A) Inhibitor AG-270 and Recombinant Methioninase Is Not Cancer-selective in a Co-culture Model of Colon Cancer Cells and Normal FibroblastsJinsoo Kim, Qinghong Han, Shukuan Li, et al.
Anticancer Research|November 29, 2025
The Combination of Recombinant Methioninase and Low-dose Chloroquine Selectively Eradicates Colon-Cancer Cells Without Apparent Toxicity on Co-cultured Normal FibroblastsJinsoo Kim, Qinghong Han, Shukuan Li, et al.
Anticancer Research|December 30, 2025
Effect of Recombinant Methioninase Dose and Timing on the Selective and Precise Elimination of Cancer Cells from Co-Cultured Normal Cells and on Methionine-dependent Rescue of Cancer CellsJinsoo Kim, Qinghong Han, Shukuan Li, et al.
Anticancer Research|October 28, 2025
Simultaneous Targeting of Multiple Hallmarks of Cancer With Recombinant Methioninase, Rapamycin and Chloroquine Is Specific and Synergistic to MiaPaCa-2 Pancreatic-Cancer Cells in Contrast to Hs-27 Normal FibroblastsJinsoo Kim, Qinghong Han, Shukuan Li, et al.
Pageof 3